PMID- 21606941
OWN - NLM
STAT- MEDLINE
DCOM- 20110726
LR  - 20220408
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Linking)
VI  - 11
IP  - 6
DP  - 2011 Jun
TI  - Targeting hypoxia in cancer therapy.
PG  - 393-410
LID - 10.1038/nrc3064 [doi]
AB  - Hypoxia is a feature of most tumours, albeit with variable incidence and severity 
      within a given patient population. It is a negative prognostic and predictive 
      factor owing to its multiple contributions to chemoresistance, radioresistance, 
      angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, 
      altered metabolism and genomic instability. Given its central role in tumour 
      progression and resistance to therapy, tumour hypoxia might well be considered 
      the best validated target that has yet to be exploited in oncology. However, 
      despite an explosion of information on hypoxia, there are still major questions 
      to be addressed if the long-standing goal of exploiting tumour hypoxia is to be 
      realized. Here, we review the two main approaches, namely bioreductive prodrugs 
      and inhibitors of molecular targets upon which hypoxic cell survival depends. We 
      address the particular challenges and opportunities these overlapping strategies 
      present, and discuss the central importance of emerging diagnostic tools for 
      patient stratification in targeting hypoxia.
FAU - Wilson, William R
AU  - Wilson WR
AD  - Auckland Cancer Society Research Centre, The University of Auckland, Auckland, 
      New Zealand. wr.wilson@auckland.ac.nz
FAU - Hay, Michael P
AU  - Hay MP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Prodrugs)
RN  - 0 (Reactive Oxygen Species)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor
MH  - *Cell Hypoxia/drug effects
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Neoplasms/blood supply/*drug therapy/*metabolism
MH  - Prodrugs/therapeutic use
MH  - Prognosis
MH  - Reactive Oxygen Species/metabolism
EDAT- 2011/05/25 06:00
MHDA- 2011/07/27 06:00
CRDT- 2011/05/25 06:00
PHST- 2011/05/25 06:00 [entrez]
PHST- 2011/05/25 06:00 [pubmed]
PHST- 2011/07/27 06:00 [medline]
AID - nrc3064 [pii]
AID - 10.1038/nrc3064 [doi]
PST - ppublish
SO  - Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064.